Lung Squamous Cell Carcinoma Subtyping via Gene Expression Signatures

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for lung cancer, particularly for squamous cell carcinoma subtypes, face challenges in accuracy and effectiveness due to limitations in distinguishing between basal, classical, primitive, and secretory subtypes, which affects prognosis and treatment response.

Innovation Solution

A method involving the detection of specific classifier biomarkers using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) or RNA sequencing to classify lung tissue samples based on the expression levels of a set of biomarkers, allowing for more precise identification of squamous cell carcinoma subtypes and prediction of treatment responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If morphological classification is used for lung cancer subtyping, then diagnosis can be performed with standard histological methods, but accuracy is reduced due to heterogeneity and limited pathologist agreement

Engineering Contradiction:

ImproveEase of diagnosisVSAvoidClassification accuracy

Core Design Contradiction:

Ease of manufactureVSMeasurement precision

Solution Approach 1:

The patent introduces gene expression profiles as an intermediary between traditional morphological classification and molecular subtyping. By measuring expression levels of specific gene sets (e.g., 208 genes, 80 genes, or 20 genes) and comparing them to reference profiles, the system achieves accurate molecular subtype classification while working with standard histological samples, thus bridging the gap between ease of diagnosis and classification accuracy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/morphological classification system (visual histological examination by pathologists) with a molecular-based system using gene expression measurement. This substitution eliminates the subjectivity and limitations of morphological assessment while maintaining compatibility with standard tissue sampling procedures

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Measurement precision

If comprehensive gene expression analysis is performed to accurately subtype lung squamous cell carcinoma, then classification accuracy improves, but device complexity and cost increase

Engineering Contradiction:

ImproveSubtype classification accuracyVSAvoidComplexity of gene expression analysis

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent extracts only the most informative gene sets from the complete genome for subtyping analysis. Instead of analyzing all genes, it identifies specific gene sets (208 genes, 80 genes, or 20 genes) that are sufficient for accurate molecular subtype classification. This extraction reduces the complexity of the analysis while maintaining classification accuracy

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent demonstrates that analyzing a partial set of genes (rather than the complete genome) is sufficient for accurate lung squamous cell carcinoma subtyping. The 20-gene signature, for example, provides a simplified yet effective approach that achieves the necessary classification accuracy without requiring comprehensive genomic analysis

Inventive Principle:

Principle #16Partial or excessive action

3Measurement precision

If more biomarkers are analyzed for squamous cell carcinoma subtyping, then classification accuracy improves, but the time and resources required increase

Engineering Contradiction:

ImproveSubtype identification accuracyVSAvoidTime for biomarker analysis

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent establishes that analyzing a limited set of 20 genes is sufficient for accurate lung squamous cell carcinoma molecular subtyping. This partial action approach achieves the necessary diagnostic accuracy without requiring analysis of hundreds or thousands of genes, thereby significantly reducing the time and resources needed for subtyping while maintaining clinical utility

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the accuracy of lung cancer subtype classification and treatment prediction, enabling more targeted and effective therapeutic strategies by distinguishing between different squamous cell carcinoma subtypes.

Implementation Method 1

quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR)

Methodology Applied

Scientific EffectReverse transcription:

Implementation Method 2

quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR)

Methodology Applied

Scientific EffectPolymerase chain reaction:

Implementation Method 3

RNA sequencing

Methodology Applied

Scientific EffectRNA sequencing:

Data Source

PatentUS12139765B2Methods for subtyping of lung squamous cell carcinoma

Publication Date: 2024.11.12 GENECENTRIC THERAPEUTICS INC

AI summary

Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.